Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNAR-2 TTFields plus pembrolizumab and platinum chemotherapy in metastatic NSCLC
jRCT2072240024Recruiting
- Sponsor
- NovoCure
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by NovoCure. Primary endpoints: Overall survival and Progression-free survival. Started Jun 2024; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2072240024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2072240024.